Combined oral and rectal mesalazine for the treatment of mild-to-moderately active ulcerative colitis: Rapid symptom resolution and improvements in quality of life

Journal of Crohn's and Colitis

Volumn 8, Issue 3, 2014, Pages 200-207

  Probert, Christopher S J ^a   Dignass, Axel U ^b   Lindgren, Stefan ^c,d   Oudkerk Pool, Marco ^e   Marteau, Philippe ^f,g  

^a UNIVERSITY OF LIVERPOOL   (United Kingdom)

^b AGAPLESION MARKUS KRANKENHAUS   (Germany)

^c LUND UNIVERSITY   (Sweden)

^d LUND UNIVERSITY HOSPITAL   (Sweden)

^e Flevoziekenhuis   (Netherlands)

^f HÔPITAL LARIBOISIÈRE   (France)

^g UNIVERSITÉ PARIS DESCARTES   (France)

Author keywords

Mesalazine; Mucosal healing; Oral; Rectal suspension; Ulcerative colitis

Indexed keywords

MESALAZINE; MUCOSAL HEALING; ORAL; RECTAL SUSPENSION; ULCERATIVE COLITIS;

ADMINISTRATION, ORAL; ADMINISTRATION, RECTAL; ADULT; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; COLITIS, ULCERATIVE; COLONOSCOPY; DOUBLE-BLIND METHOD; ENEMA; FEMALE; GASTROINTESTINAL HEMORRHAGE; HUMANS; INTESTINAL MUCOSA; MALE; MESALAMINE; QUALITY OF LIFE; RECTAL DISEASES; SEVERITY OF ILLNESS INDEX; TIME FACTORS; WOUND HEALING; YOUNG ADULT;

EID: 84894253249     PISSN: 18739946     EISSN: 18764479     Source Type: Journal    
DOI: 10.1016/j.crohns.2013.08.007     Document Type: Article

References (33)

1. Dignass A., Lindsay J.O., Sturm A., Windsor A., Colombel J.-F., Allez M., et al. Second European evidence-based Consensus on the diagnosis and management of ulcerative colitis: current management. J Crohn's Colitis 2012, 6:991-1030.
2. Wilson J. Novel 5-aminosalicylic acid formulations in ulcerative colitis: old dog, new tricks. Gastroenterol Nurs 2008, 31:286-292.
3. Dignass A.U., Bokemeyer B., Adamek H., Mross M., Vinter-Jensen L., Börner N., et al. Mesalamine once daily is more effective than twice daily in patients with quiescent ulcerative colitis. Clin Gastroenterol Hepatol 2009, 7:762-769.
4. Farup P.G., Hinterleitner T.A., Lukás M., Hébuterne X., Rachmilewitz D., Campieri M., et al. Mesalazine 4g daily given as prolonged-release granules twice daily and four times daily is at least as effective as prolonged-release tablets four times daily in patients with ulcerative colitis. Inflamm Bowel Dis 2001, 7:237-242.
5. Hanauer S., Schwartz J., Robinson M., Roufail W., Arora S., Cello J., et al. Mesalamine capsules for treatment of active ulcerative colitis: results of a controlled trial. Mesalazine Study Group. Am J Gastroenterol 1993, 88:1188-1197.
6. Hanauer S.B., Sandborn W.J., Dallaire C., Archambault A., Yacyshyn B., Yeh C., et al. Delayed-release oral mesalamine 4.8g/day (800mg tablets) compared to 2.4g/day (400mg tablets) for the treatment of mildly to moderately active ulcerative colitis: the ASCEND I trial. Can J Gastroenterol 2007, 21:827-834.
7. Miner P., Hanauer S., Robinson M., Schwartz J., Arora S. Safety and efficacy of controlled-release mesalamine for maintenance of remission in ulcerative colitis. Mesalazine UC Maintenance Study Group. Dig Dis Sci 1995, 40:296-304.
8. Sandborn W.J., Kamm M.A., Lichtenstein G.R., Lyne A., Butler T., Joseph R.E. MMX Multi Matrix System mesalazine for the induction of remission in patients with mild-to-moderate ulcerative colitis: a combined analysis of two randomized, double-blind, placebo-controlled trials. Aliment Pharmacol Ther 2007, 26:205-215.
9. Gionchetti P., Rizzello F., Venturi A., Brignola C., Ferretti M., Peruzzo S., et al. Comparison of mesalazine suppositories in proctitis and distal proctosigmoiditis. Aliment Pharmacol Ther 1997, 11:1053-1057.
10. Lémann M., Galian A., Rutgeerts P., Van Heuverzwijn R., Cortot A., Viteau J.M., et al. Comparison of budesonide and 5-aminosalicylic acid enemas in active distal ulcerative colitis. Aliment Pharmacol Ther 1995, 9:557-562.
11. Marshall J.K., Irvine E.J. Putting rectal 5-aminosalicylic acid in its place: the role in distal ulcerative colitis. Am J Gastroenterol 2000, 95:1628-1636.
12. Cohen R.D., Woseth D.M., Thisted R.A., Hanauer S.B. A meta-analysis and overview of the literature on treatment options for left-sided ulcerative colitis and ulcerative proctitis. Am J Gastroenterol 2000, 95:1263-1276.
13. Gionchetti P., Rizzello F., Venturi A., Ferretti M., Brignola C., Miglioli M., et al. Comparison of oral with rectal mesalazine in the treatment of ulcerative proctitis. Dis Colon Rectum 1998, 41:93-97.
14. Kam L., Cohen H., Dooley C., Rubin P., Orchard J. A comparison of mesalamine suspension enema and oral sulfasalazine for treatment of active distal ulcerative colitis in adults. Am J Gastroenterol 1996, 91:1338-1342.
15. Safdi M., DeMicco M., Sninsky C., Banks P., Wruble L., Deren J., et al. A double-blind comparison of oral versus rectal mesalamine versus combination therapy in the treatment of distal ulcerative colitis. Am J Gastroenterol 1997, 92:1867-1871.
16. Regueiro M., Loftus E.V., Steinhart A.H., Cohen R.D. Clinical guidelines for the medical management of left-sided ulcerative colitis and ulcerative proctitis: summary statement. Inflamm Bowel Dis 2006, 12:972-978.
17. Pimpo M.T., Galletti B., Palumbo G., Viscido A., Gentile P., Caprilli R., et al. Mesalazine vanishing time from rectal mucosa following its topical administration. J Crohn's Colitis 2010, 4:102-105.
18. Prantera C., Viscido A., Biancone L., Francavilla A., Giglio L., Campieri M. A new oral delivery system for 5-ASA: preliminary clinical findings for MMX. Inflamm Bowel Dis 2005, 11:421-427.
19. d'Albasio G., Trallori G., Gavazzi O., Bardazzi G., Vannozzi G., Frittelli G., et al. Combined therapy with 5-aminosalicylic tablets and enemas for maintaining remission in ulcerative colitis. Ital J Gastroenterol 1991, 23:12-14.
20. Piodi L.P., Ulivieri F.M., Cermesoni L., Cesana B.M. Long-term intermittent treatment with low-dose 5-aminosalicylic enemas is efficacious for remission maintenance in ulcerative colitis. Scand J Gastroenterol 2004, 39:154-157.
21. Vecchi M., Meucci G., Gionchetti P., Beltrami M., Di Maurizio P., Beretta L., et al. Oral versus combination mesalazine therapy in active ulcerative colitis: a double-blind, double-dummy, randomized multicentre study. Aliment Pharmacol Ther 2001, 15:251-256.
22. Marteau P., Probert C.S., Lindgren S., Gassul M., Tan T.G., Dignass A., et al. Combined oral and enema treatment with Pentasa (mesalazine) is superior to oral therapy alone in patients with extensive mild/moderate active ulcerative colitis: a randomised, double blind, placebo controlled study. Gut 2005, 54:960-965.
23. Flourié B., Hagège H., Tucat G., Maetz D., Hébuterne X., Kuyvenhoven J.P., et al. MOTUS study investigators. Randomised clinical trial: once- vs. twice-daily prolonged-release mesalazine for active ulcerative colitis. Aliment Pharmacol Ther 2013, 37:767-775.
24. Ford A., Achkar J.P., Khan K., Kane S., Talley N., Marshall J., et al. Efficacy of 5-aminosalicylates in ulcerative colitis: systematic review and meta-analysis. Am J Gastroenterol 2011, 106:601-616.
25. Nanda K., Moss A.C. Update on the management of ulcerative colitis: treatment and maintenance approaches focused on MMX(®) mesalamine. Clin Pharmacol 2012, 4:41-50.
26. Peyrin-Biroulet L., Ferrante M., Magro F., Campbell S., Franchimont D., Fidder H., et al. Results from the 2nd Scientific Workshop of the ECCO. I: impact of mucosal healing on the course of inflammatory bowel disease. J Crohns Colitis 2011, 5:477-483.
27. Jenkinson C., Gray A., Doll H., Lawrence K., Keoghane S., Layte R. Evaluation of index and profile measures of health status in a randomized controlled trial - comparison of the medical outcomes study 36-item short form health survey, EuroQoL and Disease Specific Measures. Med Care 1997, 35:1109-1118.
28. Marteau P., Oudkerk Pool M., Karlen P., Gassul M.A., Dignass A., Broberg P., et al. Early response to combined oral and topical mesalazine (Pentasa®) for ulcerative colitis: post-hoc analysis of efficacy at two weeks in the PINCE trial. Gastroenterology 2010, 138(Suppl. 1):S-521. [abstract T1252].
29. Connolly M.P., Poole C.D., Currie C.J., Marteau P., Nielsen S.K. Quality of life improvements attributed to combination therapy with oral and topical mesalazine in mild-to-moderately active ulcerative colitis. Digestion 2009, 80:241-246.
30. Sandborn W.J., Hanauer S., Lichtenstein G.R., Safdi M., Edeline M., Scott Harris M. Early symptomatic response and mucosal healing with mesalazine rectal suspension therapy in active distal ulcerative colitis - additional results from two controlled studies. Aliment Pharmacol Ther 2011, 34:747-756.
31. Prantera C., Rizzi M. 5-ASA in ulcerative colitis: improving treatment compliance. World J Gastroenterol 2009, 15:4353-4355.
32. Karagozian R., Burakoff R. The role of mesalamine in the treatment of ulcerative colitis. Ther Clin Risk Manage 2007, 3:893-903.
33. Probert C. Steroids and 5-aminosalicylic acids in moderate ulcerative colitis: addressing the dilemma. Ther Adv Gastroenterol 2013, 6:33-38.